Protara Therapeutics (NASDAQ:TARA – Get Free Report) and Mangoceuticals (NASDAQ:MGRX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.
Profitability
This table compares Protara Therapeutics and Mangoceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Protara Therapeutics | N/A | -38.70% | -36.02% |
| Mangoceuticals | -4,639.13% | -112.00% | -104.96% |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Protara Therapeutics and Mangoceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Protara Therapeutics | 1 | 0 | 7 | 0 | 2.75 |
| Mangoceuticals | 1 | 0 | 0 | 0 | 1.00 |
Institutional & Insider Ownership
38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Protara Therapeutics and Mangoceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Protara Therapeutics | N/A | N/A | -$57.44 million | ($1.34) | -2.99 |
| Mangoceuticals | $460,000.00 | 13.80 | -$20.64 million | ($1.49) | -0.25 |
Mangoceuticals has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Protara Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.
Summary
Protara Therapeutics beats Mangoceuticals on 7 of the 13 factors compared between the two stocks.
About Protara Therapeutics
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
